ASX Filings

Opthea Ph1 wAMD data presented at EURETINA 2016

September 12, 2016

Appendix 4E and Annual Report 2016

August 29, 2016

Appendix 4G and Corporate Governance Statement 2016

August 29, 2016

Opthea to Present at Ophthalmology Innovation Summit in US

August 8, 2016

Opthea reports positive data from Phase 1 wet AMD Trial

July 26, 2016

Opthea to Host Conference Call Update on wetAMD Trial

July 25, 2016

Change of Director's Interest Notice - MB

July 5, 2016

Appendix 3B

May 18, 2016

Change in substantial holding for ANP

May 16, 2016

Opthea Doses First Patient in Ph2A for OPT-302 in Wet AMD

May 5, 2016